A New Phase of Execution: Funding, Focus, and Forward Motion: Cortexa Therapeutics is entering a pivotal stage—where disciplined execution meets scientific clarity. We're no longer chasing headlines; we're building a lean, data-driven pipeline focused on one thing: impact.

Our immediate goal? Generate robust in vitro data on a set of novel compounds targeting a mechanism increasingly implicated in neurodegeneration. Breakthroughs start here.

This week’s focus: fiscal sponsorship, neurotoxicity, and how your support can help rewrite the future of ALS treatment. We’re partnering with Mission Edge to accept tax-deductible donations—a major leap forward in how we fund research without becoming a full nonprofit. Every dollar will go straight to the lab, not to overhead or salaries. We’re building toward the synthesis and testing of new analogs—first steps in an IND-enabling campaign. The goal? Intercept neurodegeneration at its root.

Cortexa is filing a provisional patent and incorporating as a C-Corp, marking major milestones in our mission to fast-track neuroprotective therapies for ALS. We're also first in line for a DOD ALSRP grant, advancing our approach targeting calcium dysregulation as a root cause.

Cortexa Therapeutics shares major updates: a CNS-focused medicinal chemist joins the team, business development gains momentum, and new research on cortical hyperexcitability in ALS informs our evolving strategy. Stay connected to our mission to transform ALS treatment through innovative science and community-driven progress.

Neuroscience insights, startup updates, and what I’m thinking about this week. We’re moving fast. This week, we’ve been finalizing our shortlist of medicinal chemists to begin designing next-generation analogs based on our early scaffold work.

From Diagnosis to Discovery: Nathan Cole’s Fight Against ALS with Cortexa Therapeutics. With a mission grounded in urgency, resilience, and innovation, Cortexa is developing precision therapies to restore balance to the nervous system and bring hope to families facing ALS.